Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qiagen's TB Test Cuts Estimate of Latent TB Incidence in China

publication date: Feb 11, 2015
In China's largest pivotal trial ever -- 21, 000 people -- Qiagen's TB test showed the incidence of latent TB infection in China's population is 18.8%. That was far lower than the 28.8% indicated by the century-old TB skin test, which registered many false positives. The QuantiFERON-TB Gold (QFT®) test, an interferon-gamma release assay, was approved for use in China in 2013. By lowering the estimate of China's at-risk population, the test renders a TB preventative program more feasible. Qiagen is headquartered in the Netherlands. More details....

Stock Symbol: (NSDQ: QGEN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital